<table id="table8" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8:  Established Drug Interactions with VIDEX </caption>
<colgroup>
<col width="20%"></col>
<col align="center" width="30%"></col>
<col width="50%"></col>
</colgroup>
<thead>
<tr>
<th>Drug</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↑  Indicates increase.</td>
</tr>
<tr>
<td align="left" colspan="3">↓  Indicates decrease.</td>
</tr>
<tr>
<td align="left" colspan="3">
<sup>a</sup>  The dosing recommendation for coadministration of VIDEX EC and tenofovir disoproxil fumarate with respect to meal consumption differs from that of VIDEX. See the complete prescribing information for VIDEX EC.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" valign="top">ciprofloxacin</td>
<td valign="top">↓ ciprofloxacin concentration</td>
<td align="left" valign="top">Administer VIDEX at least 2 hours after or 6 hours before ciprofloxacin. </td>
</tr>
<tr>
<td align="left" valign="top">delavirdine</td>
<td valign="top">↓ delavirdine concentration</td>
<td align="left" valign="top">Administer VIDEX 1 hour after delavirdine.
											</td>
</tr>
<tr>
<td align="left" valign="top">ganciclovir</td>
<td valign="top">↑ didanosine concentration</td>
<td align="left" valign="top">If there is no suitable alternative to ganciclovir, then use in combination with VIDEX with caution. Monitor for didanosine-associated toxicity. </td>
</tr>
<tr>
<td align="left" valign="top">indinavir</td>
<td valign="top">↓ indinavir concentration</td>
<td align="left" valign="top">Administer VIDEX 1 hour after indinavir. </td>
</tr>
<tr>
<td align="left" valign="top">methadone</td>
<td valign="top">↓ didanosine concentration</td>
<td align="left" valign="top">Do not coadminister methadone with VIDEX pediatric powder due to significant decreases in didanosine concentrations. If coadministration of methadone and didanosine is necessary, the recommended formulation of didanosine is VIDEX EC. Patients should be closely monitored for adequate clinical response when VIDEX EC is coadministered with methadone, including monitoring for changes in HIV RNA viral load.</td>
</tr>
<tr>
<td align="left" valign="top">nelfinavir</td>
<td valign="top">No interaction 1 hour after didanosine</td>
<td align="left" valign="top">Administer nelfinavir 1 hour after VIDEX. </td>
</tr>
<tr>
<td align="left" valign="top">tenofovir disoproxil fumarate</td>
<td valign="top">↑ didanosine concentration</td>
<td align="left" valign="top">A dose reduction of VIDEX to the following dosage once daily is recommended.<sup>a</sup>
<br/>
<list listtype="unordered" stylecode="Disc">
<item>250 mg (adults weighing at least 60 kg with creatinine clearance of at least 60 mL/min)</item>
<item>200 mg (adults weighing less than 60 kg with creatinine clearance of at least 60 mL/min)</item>
</list>VIDEX and tenofovir disoproxil fumarate may be taken together in the fasted state. If tenofovir disoproxil fumarate is taken with food, VIDEX should be taken on an empty stomach (at least 30 minutes before food or 2 hours after food). Patients should be monitored for didanosine-associated toxicities and clinical response.</td>
</tr>
</tbody>
</table>